Immunology / Virology & Vaccines

#Covid-19 #Immunology / Virology & Vaccines

Novavax COVID-19 vaccine candidate data at New York Academy of Science

Novavax has announced that Gregory Glenn, President of Research & Development, will present on NVX-CoV2373, the company’s COVID-19 vaccine, at The New York Academy of Science (NYAS) event, ‘The Quest for a COVID-19 Vaccine.’ Webinar details are as follows: Presentation title: Efficacy Data Updates from Novavax’ Protein-based Vaccine Candidate Date:  … Read More

#Covid-19 #News

#Immune response #Immunology / Virology & Vaccines

Most immunosuppressed children safe to have vaccines

Both inactivated and live-attenuated vaccines generally produce an adequate immune response and are safe to use in children suffering with autoimmune diseases treated with all but the most potent immunosuppressants, according to a research review. A team from The University of Manchester and Manchester University NHS Foundation Trust examined 37… Read More

#Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines

Janssen COVID-19 vaccine: 66% efficacy in one shot

An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase III clinical data. The vaccine, called Ad.26.COV2.S or JNJ-78436725, requires only a single injection and can be stored in a refrigerator… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Novavax COVID-19 vaccine demonstrates 89.3% efficacy

Novavax, the biotechnology company developing next-generation vaccines for serious infectious diseases, has announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase III clinical trial conducted in the UK. The study assessed efficacy during a period with high transmission… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Events #Immunology / Virology & Vaccines #RNA

RNA Anti-Infectives Symposium

Two weeks ago, the Moderna mRNA vaccine became the third vaccine to be approved for emergency use in the UK. With 94% effectiveness, this vaccine is an exciting addition to the COVID-19 relief effort and brings us one step closer to the end of the pandemic. Before 2020, efforts to study mRNA vaccines… Read More

#Editor's Choice #News

#Covid-19 #Flow Cytometry #Immunology / Virology & Vaccines

DDW App Note: The ZE5 Cell Analyzer in the fight against COVID-19

This paid-for app note by Bio-Rad appeared in DDW Volume 22, Issue 1 – Winter 2020/21. As COVID-19 has taken the world by storm, much has been learnt about the various aspects of viral infections ranging from immune surveillance to the therapeutic development of vaccines. One of the technologies that… Read More

#Exclusive Content

#Covid-19 #Immunology / Virology & Vaccines

Moderna vaccine protective against UK and South African variants

Moderna has released results from in vitro neutralisation studies of sera from individuals vaccinated with its COVID-19 vaccine showing activity against emerging strains of SARS-CoV-2. Vaccination with the Moderna COVID-19 vaccine produced neutralising titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and… Read More

#News #Trending News

#Drug development #Immunology / Virology & Vaccines

Why Nexelis is ‘changing the R&D paradigm in vaccines’

Benoit Bouche, President and CEO, Nexelis, told Lu Rahman about the company’s recent acquisition and what it means for the business and the vaccine sector. Nexelis is a leading provider of assay development and advanced laboratory testing services in the infectious diseases, metabolic diseases, and oncology fields. The company –… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Covid-19 #Immunology / Virology & Vaccines

Novavax and Canadian government purchase agreement for COVID-19 vaccine

Novavax, the late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, has finalised an agreement with the government of Canada to supply up to 76 million doses of NVX-CoV2373, the company’s recombinant protein-based COVID-19 vaccine. Canada has committed to purchase 52 million doses of the vaccine with the option… Read More

#Covid-19 #News #Trending News

#Assay development & optimisation #Immunology / Virology & Vaccines

Nexelis aquires GSK Vaccines’ German clinical bioanalytical lab

Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields, has signed an asset purchase agreement with GSK to acquire its GCLP-certified clinical bioanalytical laboratory located in Marburg, Germany. The Clinical Laboratory… Read More

#News

#Immunology / Virology & Vaccines #Mass spectrometry / NMR

It’s all in the technique: how MS provides information on virus structure and function

Andreas Huhmer, Senior Director, Proteomics and Metabolomics, Thermo Fisher Scientific, examines the mass spectrometry techniques providing detailed insight into virus structure and function Our ability to quickly and accurately understand new viruses has been significantly tested in 2020, with the emergence of SARS-CoV-2, the coronavirus causing the COVID-19 pandemic. Since… Read More

#Exclusive Content